31-okt-2013 Bayer continue
s positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter /
New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group gu
...[+++]idance for 2013 maintained » meer31-oct.-2013 Bayer continue
s positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter /
New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group g
...[+++]uidance for 2013 maintained » En savoir plus